Alzheimer's Props Lilly Growth Prospects After Evacetrapib
This article was originally published in Scrip
Eli Lilly & Co. is embarking on a rough forecast period, with analysts predicting a continuing decline in sales for the firm's central nervous system (CNS) franchise. However, calmer seas might be ahead if the ongoing trial for its Alzheimer's disease (AD) antibody solanezumab yields positive results and if growth products can reach their targets by year 2019.
You may also be interested in...
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.